Investment Summary |
|
|---|---|
| Date | 2023-12-19 |
| Target | Castelein Sealants |
| Sector | Distribution |
| Investor(s) | GIMV |
| Deal Type | Growth Capital |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 159 of 170 |
| Sector: Distribution M&A | 5 of 5 |
| Type: Growth Capital M&A Deals | 31 of 34 |
| Country: Belgium M&A | 47 of 50 |
| Year: 2023 M&A | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-12-08 |
WEMAS
Gutersloh, Germany WEMAS is a manufacturer of products for mobile passive security of construction sites mainly in public road traffic situations. The company supplies both wholesalers as well as roadsafety service providers responsible for the road safety of highway construction sites, infrastructure and construction sites, predominantly in the DACH region and adjacent markets. WEMAS was founded in 1971 and is based in Gutersloh, Germany. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-04-22 |
SynOx Therapeutics
Dublin, Ireland SynOx Therapeutics develops Emactuzumab a potential best-in-class clinical-stage CSF-1R targeted antibody designed to target and deplete macrophages in the tumour tissue. It has shown a favourable safety profile and encouraging efficacy in patients with diffuse tenosynovial giant cell tumours (dTGCT), a rare oncology disease. SynOx Therapeutics was founded in 2020 and is based in Dublin, Ireland. |
Sell | - |
